{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:29:45Z","timestamp":1792178985880,"version":"4.4.0"},"reference-count":145,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T00:00:00Z","timestamp":1548115200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Brazilian Society of Rheumatology","award":["."],"award-info":[{"award-number":["."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s42358-019-0048-x","type":"journal-article","created":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T15:01:44Z","timestamp":1548255704000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Guidelines of the Brazilian Society of Rheumatology for the treatment of systemic autoimmune myopathies"],"prefix":"10.1186","volume":"59","author":[{"given":"Fernando Henrique Carlos","family":"de Souza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Brito","family":"de Ara\u00fajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f4nica Silva","family":"Vilela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mailze Campos","family":"Bezerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo Santos","family":"Sim\u00f5es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanderley Marques","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Miossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo Matos","family":"da Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel Katsuyuki","family":"Shinjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,22]]},"reference":[{"key":"48_CR1","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0140-6736(08)60955-1","volume":"371","author":"BM Feldman","year":"2008","unstructured":"Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008;371:201\u201312.","journal-title":"Lancet"},{"key":"48_CR2","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1002\/art.40320","volume":"69","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tjamlund A, Bottai M, Pikington C, de Visser M, Alfredson L, et al. 2017 European league against rheumatism\/ American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheum. 2017;69:2271\u201382.","journal-title":"Arthritis Rheum"},{"key":"48_CR3","doi-asserted-by":"crossref","unstructured":"Gordon PA, Winer JB, Hoogendijk JE, Choy EH. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev. 2012:CD003643.","DOI":"10.1002\/14651858.CD003643.pub4"},{"key":"48_CR4","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/BOR.0000000000000430","volume":"29","author":"V Leclair","year":"2017","unstructured":"Leclair V, Lundberg IE. Recent clinical trials in idiopathic inflammatory myopathies. Curr Opin Rheumatol. 2017;29:652\u201365.","journal-title":"Curr Opin Rheumatol"},{"key":"48_CR5","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Iberati","year":"2009","unstructured":"Iberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.","journal-title":"BMJ"},{"key":"48_CR6","unstructured":"Oxford centre for evidence-based medicine - Levels of evidence (March 2009) - CEBM. 2009."},{"key":"48_CR7","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/bmj.39493.646875.AE","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, GRADE Working Group, et al. Going from evidence to recommendations. BMJ. 2008;336:1049\u201351.","journal-title":"BMJ"},{"key":"48_CR8","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, GRADE Working Group, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u20136.","journal-title":"BMJ"},{"key":"48_CR9","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.otc.2013.08.006","volume":"46","author":"MA Kuhn","year":"2013","unstructured":"Kuhn MA, Belafsky PC. Management of cricopharyngeus muscle dysfunction. Otolaryngol Clin N Am. 2013;46:1087\u201399.","journal-title":"Otolaryngol Clin N Am"},{"key":"48_CR10","doi-asserted-by":"publisher","first-page":"441","DOI":"10.4065\/82.4.441","volume":"82","author":"TH Oh","year":"2007","unstructured":"Oh TH, Brumfield KA, Hoskin TL, Stolp KA, Murray JA, Brassford JR. Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients. Mayo Clin Proc. 2007;82:441\u20137.","journal-title":"Mayo Clin Proc"},{"key":"48_CR11","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jns.2017.07.031","volume":"380","author":"A Schrey","year":"2017","unstructured":"Schrey A, Airas L, Jokela M, Pulkkinen J. Botulinum toxin alleviates dysphagia of patients with inclusion body myositis. J Neurol Sci. 2017;380:142\u20137.","journal-title":"J Neurol Sci"},{"key":"48_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/PL00007520","volume":"259","author":"M Moerman","year":"2002","unstructured":"Moerman M, Callier Y, Dick C, Vermeersch H. Botulinum toxin for dysphagia due to cricopharyngeal dysfunction. Eur Arch Otorhinolaryngol. 2002;259:1\u20133.","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"48_CR13","doi-asserted-by":"crossref","unstructured":"Sanei-Moghaddam A, Kumar S, Jani P, Brierley C. Cricopharyngeal myotomy for cricopharyngeus stricture in an inclusion body myositis patient with hiatus hernia: a learning experience. BMJ Case Rep. 2013;2013.","DOI":"10.1136\/bcr-2012-008058"},{"key":"48_CR14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.semarthrit.2010.08.003","volume":"41","author":"I Marie","year":"2011","unstructured":"Marie I, Mcnard JF, Hachulla E, Ch\u00e9rin P, Benveniste O, Tiev K, et al. Infectious complications in polymyositis and dermatomyositis: a series of 279 patients. Semin Arthritis Rheum. 2011;41:48\u201360.","journal-title":"Semin Arthritis Rheum"},{"key":"48_CR15","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jaad.2009.07.042","volume":"62","author":"JL Gerhart","year":"2010","unstructured":"Gerhart JL, Kalaaji AN. Development of Pneumocystis carinii pneumonia in patients with immunobullous and connective tissue disease receiving immunosuppressive medications. J Am Acad Dermatol. 2010;62:957\u201361.","journal-title":"J Am Acad Dermatol"},{"key":"48_CR16","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/01.rhu.0000221794.24431.36","volume":"12","author":"J Li","year":"2006","unstructured":"Li J, Huang XM, Fang WG, Zeng XJ. Pneumocystis carinii pneumonia in patients with connective tissue disease. J Clin Rheumatol. 2006;12:114\u20137.","journal-title":"J Clin Rheumatol"},{"key":"48_CR17","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/1529-0131(199904)42:4<780::AID-ANR23>3.0.CO;2-M","volume":"42","author":"MM Ward","year":"1999","unstructured":"Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum. 1999;42:780\u20139.","journal-title":"Arthritis Rheum"},{"key":"48_CR18","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1001\/archinte.1997.00440340145015","volume":"157","author":"H Bachelez","year":"1997","unstructured":"Bachelez H, Schremmer B, Cadranel J, Mouly F, Sarfati C, Agbalika F, et al. Fulminant Pneumocystis carinii pneumonia in 4 patients with dermatomyositis. Arch Intern Med. 1997;157:1501\u20133.","journal-title":"Arch Intern Med"},{"key":"48_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4065\/71.1.5","volume":"71","author":"SH Yale","year":"1996","unstructured":"Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996;71:5\u201313.","journal-title":"Mayo Clin Proc"},{"key":"48_CR20","first-page":"1186","volume":"23","author":"A Kadoya","year":"1996","unstructured":"Kadoya A, Okada J, Iikuni Y, Kondo H. Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis\/dermatomyositis or systemic lupus erythematosus. J Rheumatol. 1996;23:1186\u20138.","journal-title":"J Rheumatol"},{"key":"48_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11926-017-0664-6","volume":"19","author":"RM Wolfe","year":"2017","unstructured":"Wolfe RM, Peacock JE Jr. Pneumocystis pneumonia (PCP) and the rheumatologist: which patients are at risk and how can PCP be prevented? Curr Rheumatol Rep. 2017;19:35.","journal-title":"Curr Rheumatol Rep"},{"key":"48_CR22","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.annder.2016.09.677","volume":"144","author":"M Aymonier","year":"2017","unstructured":"Aymonier M, Abed S, Boy T, Barazzutti H, Fournier B, Morand JJ. Dermatomyositis associated with anti-MDA5 antibodies and Pneumocystis pneumonia: two lethal cases. Ann Dermatol Venereol. 2017;144:279\u201383.","journal-title":"Ann Dermatol Venereol"},{"key":"48_CR23","doi-asserted-by":"crossref","unstructured":"Stern A, Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev. 2014:CD005590.","DOI":"10.1002\/14651858.CD005590.pub3"},{"key":"48_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13075-016-1206-8","volume":"19","author":"M Utsunomiya","year":"2017","unstructured":"Utsunomiya M, Dobashi H, Odani T, Saito K, Yokogawa N, Nagasaka K, et al. Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial. Arthritis Res Ther. 2017;19:7.","journal-title":"Arthritis Res Ther."},{"key":"48_CR25","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1080\/00365540410015222","volume":"36","author":"P Ravn","year":"2004","unstructured":"Ravn P, Munk ME, Andersen AB, Lundgren B, Nielsen LN, Lillebaek T, et al. Reactivation of tuberculosis during immunosuppressive treatment in a patient with a positive QuantiFERON-RD1 test. Scand J Infect Dis. 2004;36:499\u2013501.","journal-title":"Scand J Infect Dis"},{"key":"48_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/art.21705","volume":"55","author":"SS Jick","year":"2006","unstructured":"Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum. 2006;55:19\u201326.","journal-title":"Arthritis Rheum"},{"key":"48_CR27","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/jcpt.12644","volume":"43","author":"MJ Chan","year":"2018","unstructured":"Chan MJ, Wen YH, Huang YB, Chuang HY, Tain YL, Lily Wang YC, et al. Risk of tuberculosis comparison in new users of anti-tumour necrosis factor and with existing disease-modifying antirheumatic drug therapy. J Clin Pharm Ther. 2018;43:256\u201364.","journal-title":"J Clin Pharm Ther"},{"key":"48_CR28","first-page":"9","volume":"16","author":"HA Kim","year":"1998","unstructured":"Kim HA, Yoo CD, Baek HJ, Lee EB, Ahn C, Han JS, et al. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. Clin Exp Rheumatol. 1998;16:9\u201313.","journal-title":"Clin Exp Rheumatol"},{"key":"48_CR29","volume-title":"Ministry of Health","author":"Health Surveillance Guide","year":"2017","unstructured":"Health Surveillance Guide, 2017, Ministry of Health."},{"key":"48_CR30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s10096-005-0070-2","volume":"25","author":"CS Lam","year":"2006","unstructured":"Lam CS, Tong MK, Chan KM, Siu YP. Disseminated strongyloidiasis: a retrospective study of clinical course and outcome. Eur J Clin Microbiol Infect Dis. 2006;25:14\u20138.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"48_CR31","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.ejim.2009.09.001","volume":"20","author":"M Santiago","year":"2009","unstructured":"Santiago M, Leito B. Prevention of strongyloides hyperinfection syndrome: a rheumatological point of view. Eur J Intern Med. 2009;20:744\u20138.","journal-title":"Eur J Intern Med"},{"key":"48_CR32","first-page":"526","volume":"27","author":"JS Davis","year":"2003","unstructured":"Davis JS, Currie BJ, Fisher DA, Huffam SE, Anstey NM, Price RN, et al. Prevention of opportunistic infections in immunosuppressed patients in the tropical top end of the Northern Territory. Commun Dis Intell Q Rep. 2003;27:526\u201332.","journal-title":"Commun Dis Intell Q Rep"},{"key":"48_CR33","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.vaccine.2012.10.063","volume":"31","author":"SK Shinjo","year":"2012","unstructured":"Shinjo SK, de Moraes JC, Levy-Neto M, Aikawa NE, de Medeiros Ribeiro AC, Schahin Saad CG, et al. Pandemic unadjuvanted influenza a (H1N1) vaccine in dermatomyositis and polymyositis: immunogenicity independent of therapy and no harmful effect in disease. Vaccine. 2012;31:202\u20136.","journal-title":"Vaccine"},{"key":"48_CR34","first-page":"583","volume":"30","author":"VR Guissa","year":"2012","unstructured":"Guissa VR, Pereira RM, Sallum AM, Aikawa NE, Campos LM, Silva CA, et al. Influenza a H1N1\/2009 vaccine in juvenile dermatomyositis: reduced immunogenicity in patients under immunosuppressive therapy. Clin Exp Rheumatol. 2012;30:583\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"48_CR35","first-page":"w14159","volume":"145","author":"S Bruhler","year":"2015","unstructured":"Bruhler S, Eperon G, Ribi C, Kyburz D, van Gompel F, Visser LG, et al. Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases. Swiss Med Wkly. 2015;145:w14159.","journal-title":"Swiss Med Wkly"},{"key":"48_CR36","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00296-013-2907-9","volume":"34","author":"D Papadopoulou","year":"2014","unstructured":"Papadopoulou D, Sipsas NV. Comparison of national clinical practice guidelines and recommendations on vaccination of adult patients with autoimmune rheumatic diseases. Rheumatol Int. 2014;34:151\u201363.","journal-title":"Rheumatol Int"},{"key":"48_CR37","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.autrev.2010.12.003","volume":"10","author":"S Assen van","year":"2011","unstructured":"van Assen S, Elkayam O, Agmon-Levin N, Cervera R, Doran MF, Dougados M, et al. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European league against rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. Autoimmun Rev. 2011;10:341\u201352.","journal-title":"Autoimmun Rev"},{"key":"48_CR38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.urology.2016.07.030","volume":"100","author":"EL Matz","year":"2017","unstructured":"Matz EL, Hsieh MH. Review of advances in uroprotective agents for cyclophosphamide and ifosfamide-induced hemorrhagic cystitis. Urology. 2017;100:16\u20139.","journal-title":"Urology"},{"key":"48_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40520-015-0522-1","volume":"28","author":"C Cooper","year":"2016","unstructured":"Cooper C, Bardin T, Brandi ML, Cacoub P, Caminis J, Civitelli R, et al. Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Aging Clin Exp Res. 2016;28:1\u201316.","journal-title":"Aging Clin Exp Res"},{"key":"48_CR40","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1007\/s12020-015-0639-1","volume":"49","author":"WF Lems","year":"2015","unstructured":"Lems WF, Saag K. Bisphosphonates and glucocorticoid-induced osteoporosis: cons. Endocrine. 2015;49:628\u201334.","journal-title":"Endocrine"},{"key":"48_CR41","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/978-1-4615-4857-7_54","volume":"455","author":"HD Bolosiu","year":"1999","unstructured":"Bolosiu HD, Man L, Rednic S. The effect of methylprednisolone pulse therapy in polymyositis\/dermatomyositis. Adv Exp Med Biol. 1999;455:349\u201357.","journal-title":"Adv Exp Med Biol"},{"key":"48_CR42","first-page":"545","volume":"43","author":"RK Winkelmann","year":"1968","unstructured":"Winkelmann RK, Mulder DW, Lambert EH, Howard FM Jr, Diessner GR. Course of dermatomyositis-polymyositis: comparison of untreated and cortisone-treated patients. Mayo Clin Proc. 1968;43:545\u201356.","journal-title":"Mayo Clin Proc"},{"key":"48_CR43","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/0002-9343(83)90344-3","volume":"75","author":"GS Hoffman","year":"1983","unstructured":"Hoffman GS, Franck WA, Raddatz DA, Stallones L. Presentation, treatment, and prognosis of idiopathic inflammatory muscle disease in a rural hospital. Am J Med. 1983;75:433\u20138.","journal-title":"Am J Med"},{"key":"48_CR44","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0165-5728(97)00033-7","volume":"76","author":"S Matsubara","year":"1997","unstructured":"Matsubara S, Hirai S, Sawa Y. Pulsed intravenous methylprednisolone therapy for inflammatory myopathies: evaluation of the effect by comparing two consecutive biopsies from the same muscle. J Neuroimmunol. 1997;76:75\u201380.","journal-title":"J Neuroimmunol"},{"key":"48_CR45","doi-asserted-by":"publisher","first-page":"58","DOI":"10.4103\/0028-3886.60398","volume":"58","author":"P Naji","year":"2010","unstructured":"Naji P, Shahram F, Nadji A, Davatchi F. Effect of early treatment in polymyositis and dermatomyositis. Neurol India. 2010;58:58\u201361.","journal-title":"Neurol India"},{"key":"48_CR46","first-page":"766","volume":"35","author":"FHC Souza De","year":"2017","unstructured":"De Souza FHC, Miossi R, Shinjo SK. Necrotising myopathy associated with anti-signal recognition particle (anti-SRP) antibody. Clin Exp Rheumatol. 2017;35:766\u201371.","journal-title":"Clin Exp Rheumatol"},{"key":"48_CR47","first-page":"310","volume":"33","author":"MM Pinhata","year":"2015","unstructured":"Pinhata MM. Nascimento, Marie SK, Shinjo SK. Does previous corticosteroid treatment affect the inflammatory infiltrate found in polymyositis muscle biopsies? Clin Exp Rheumatol. 2015;33:310\u20134.","journal-title":"Clin Exp Rheumatol"},{"key":"48_CR48","first-page":"336","volume":"33","author":"SK Shinjo","year":"2015","unstructured":"Shinjo SK, Nascimento JJ, Marie SK. The effect of prior corticosteroid use in muscle biopsies from patients with dermatomyositis. Clin Exp Rheumatol. 2015;33:336\u201340.","journal-title":"Clin Exp Rheumatol"},{"key":"48_CR49","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/0002-9343(93)90148-I","volume":"94","author":"MM Joffe","year":"1993","unstructured":"Joffe MM, Love LA, Leff RL, Fraser DD, Targoff IN, Hicks JE, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med. 1993;94:379\u201387.","journal-title":"Am J Med"},{"key":"48_CR50","doi-asserted-by":"crossref","unstructured":"Fry CS, Nayeem SZ, Dillon EL, Sarkar PS, Tumurbaatar B, Urban RJ, et al. Glucocorticoids increase skeletal muscle NF-\u03baB inducing kinase (NIK): links to muscle atrophy. Physiol Rep. 2016;4.","DOI":"10.14814\/phy2.13014"},{"key":"48_CR51","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/00124743-199504000-00007","volume":"1","author":"ED Newman","year":"1995","unstructured":"Newman ED, Scott DW. The use of low-dose oral methotrexate in the treatment of polymyositis and dermatomyositis. J Clin Rheumatol. 1995;1:99\u2013102.","journal-title":"J Clin Rheumatol"},{"key":"48_CR52","doi-asserted-by":"publisher","first-page":"365","DOI":"10.7326\/0003-4819-92-3-365","volume":"92","author":"TW Bunch","year":"1980","unstructured":"Bunch TW, Worthington JW, Combs JJ, Ilstrup DM, Engel AG. Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med. 1980;92:365\u20139.","journal-title":"Ann Intern Med"},{"key":"48_CR53","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/art.1780240107","volume":"24","author":"TW Bunch","year":"1981","unstructured":"Bunch TW. Prednisone and azathioprine for polymyositis: long-term follow-up. Arthritis Rheum. 1981;24:45\u20138.","journal-title":"Arthritis Rheum"},{"key":"48_CR54","doi-asserted-by":"publisher","first-page":"R22","DOI":"10.1186\/ar3704","volume":"14","author":"E Schiopu","year":"2012","unstructured":"Schiopu E, Phillips K, MacDonald PM, Crofford LJ, Somers EC. Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Res Ther. 2012;14:R22.","journal-title":"Arthritis Res Ther"},{"key":"48_CR55","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s10067-011-1840-0","volume":"30","author":"KH Yu","year":"2011","unstructured":"Yu KH, Wu YJ, Kuo CF, See LC, Shen YM, Chang HC, et al. Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases. Clin Rheumatol. 2011;30:1595\u2013601.","journal-title":"Clin Rheumatol"},{"key":"48_CR56","first-page":"1092","volume":"21","author":"P Cherin","year":"1994","unstructured":"Cherin P, Piette JC, Wechsler B, Bletry O, Ziza JM, Laraki R, et al. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. J Rheumatol. 1994;21:1092\u20137.","journal-title":"J Rheumatol"},{"key":"48_CR57","first-page":"29","volume":"10","author":"I G\u00f6ttfried","year":"2000","unstructured":"G\u00f6ttfried I, Seeber A, Anegg B, Rieger A, Stingl G, Volc-Platzer B. High dose intravenous immunoglobulin (IVIG) in dermatomyositis: clinical responses and effect on sIL-2R levels. Eur J Dermatol. 2000;10:29\u201335.","journal-title":"Eur J Dermatol"},{"key":"48_CR58","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.semarthrit.2016.07.014","volume":"46","author":"S Anh-Tu Hoa","year":"2017","unstructured":"Anh-Tu Hoa S, Hudson M. Critical review of the role of intravenous immunoglobulins in idiopathic inflammatory myopathies. Semin Arthritis Rheum. 2017;46:488\u2013508.","journal-title":"Semin Arthritis Rheum"},{"key":"48_CR59","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1016\/S0140-6736(99)01927-3","volume":"353","author":"CV Oddis","year":"1999","unstructured":"Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet. 1999;353:1762\u20133.","journal-title":"Lancet"},{"key":"48_CR60","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3346\/jkms.2003.18.1.131","volume":"18","author":"HK Chang","year":"2003","unstructured":"Chang HK, Lee DH. Successful combination therapy of cyclosporine and methotrexate for refractory polymyositis with anti-Jo-1 antibody: a case report. J Korean Med Sci. 2003;18:131\u20134.","journal-title":"J Korean Med Sci"},{"key":"48_CR61","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1080\/030097400750002102","volume":"29","author":"H Mitsunaka","year":"2000","unstructured":"Mitsunaka H, Tokuda M, Hiraishi T, Dobashi H, Takahara J. Combined use of cyclosporine a and methotrexate in refractory polymyositis. Scand J Rheumatol. 2000;29:192\u20134.","journal-title":"Scand J Rheumatol"},{"key":"48_CR62","first-page":"2855","volume":"27","author":"KA Qushmaq","year":"2000","unstructured":"Qushmaq KA, Chalmers A, Esdaile JM. Cyclosporin a in the treatment of refractory adult polymyositis\/dermatomyositis: population based experience in 6 patients and literature review. J Rheumatol. 2000;27:2855\u20139.","journal-title":"J Rheumatol"},{"key":"48_CR63","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/1529-0131(199803)41:3<392::AID-ART3>3.0.CO;2-X","volume":"41","author":"L Villalba","year":"1998","unstructured":"Villalba L, Hicks JE, Adams EM, Sherman JB, Gourley MF, Leff RL, et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum. 1998;41:392\u20139.","journal-title":"Arthritis Rheum"},{"key":"48_CR64","first-page":"895","volume":"42","author":"S Nakashima","year":"2002","unstructured":"Nakashima S, Mori M, Miyamae T, Ito S, Ibe M, Aihara Y, et al. Intravenous cyclophosphamide pulse therapy for refractory juvenile dermatomyositis. Ryumachi. 2002;42:895\u2013902.","journal-title":"Ryumachi"},{"key":"48_CR65","doi-asserted-by":"publisher","first-page":"749","DOI":"10.2169\/internalmedicine.32.749","volume":"32","author":"F Hirano","year":"1993","unstructured":"Hirano F, Tanaka H, Nomura Y, Matsui T, Makino Y, Fukawa E, et al. Successful treatment of refractory polymyositis with pulse intravenous cyclophosphamide and low-dose weekly oral methotrexate therapy. Intern Med. 1993;32:749\u201352.","journal-title":"Intern Med"},{"key":"48_CR66","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/archderm.142.1.65","volume":"142","author":"JC Edge","year":"2006","unstructured":"Edge JC, Outland JD, Dempsey JR, Callen JP. Mycophenolate mofetil as an effective corticosteroid sparing therapy for recalcitrant dermatomyositis. Arch Dermatol. 2006;142:65\u20139.","journal-title":"Arch Dermatol"},{"key":"48_CR67","first-page":"1011","volume":"35","author":"RC Souza De","year":"2017","unstructured":"De Souza RC, De Souza FHC, Miossi R, Shinjo SK. Efficacty and safety of leflunomide as na adjuvante drug in refractory dermatomyositis with primarily cutaneous activity. Clin Exp Rheumatol. 2017;35:1011\u20133.","journal-title":"Clin Exp Rheumatol"},{"key":"48_CR68","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3109\/s10165-007-0013-0","volume":"18","author":"E Saito","year":"2008","unstructured":"Saito E, Koike T, Hashimoto H, Miyasaka N, Ikeda Y, Hara M, et al. Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis. Mod Rheumatol. 2008;18:34\u201344.","journal-title":"Mod Rheumatol"},{"key":"48_CR69","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"MC Dalakas","year":"1993","unstructured":"Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993\u20132000.","journal-title":"N Engl J Med"},{"key":"48_CR70","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/art.10053","volume":"46","author":"P Cherin","year":"2002","unstructured":"Cherin P, Pelletier S, Teixeira A, Laforet P, Genereau T, Simon A, et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum. 2002;46:467\u201374.","journal-title":"Arthritis Rheum"},{"key":"48_CR71","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.revmed.2006.12.001","volume":"28","author":"D Wendling","year":"2007","unstructured":"Wendling D, Prati C, Ornetti P, Toussirot E, Streit G. Anti TNF-alpha treatment of a refractory polymyositis. Rev Med Interne. 2007;28:194\u20135.","journal-title":"Rev Med Interne"},{"key":"48_CR72","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1136\/ard.2007.077974","volume":"67","author":"M Dastmalchi","year":"2008","unstructured":"Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis. 2008;67:1670\u20137.","journal-title":"Ann Rheum Dis"},{"key":"48_CR73","first-page":"1802","volume":"33","author":"F Iannone","year":"2006","unstructured":"Iannone F, Scioscia C, Falappone PC, Covelli M, Lapadula G. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol. 2006;33:1802\u20134.","journal-title":"J Rheumatol"},{"key":"48_CR74","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/ana.22607","volume":"70","author":"AA Amato","year":"2011","unstructured":"Amato AA, Tawil R, Kissel J, Barohn R, McDermott MP, Pandya S, et al. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol. 2011;70:427\u201336.","journal-title":"Ann Neurol"},{"key":"48_CR75","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1136\/annrheumdis-2017-211751","volume":"77","author":"A Tj\u00e4rnlund","year":"2018","unstructured":"Tj\u00e4rnlund A, Tang Q, Wick C, Dastmalchi M, Mann H, Tomasov\u00e1 Stud\u00fdnkov\u00e1 J, et al. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. Ann Rheum Dis. 2018;77:55\u201362.","journal-title":"Ann Rheum Dis"},{"key":"48_CR76","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1093\/rheumatology\/ker152","volume":"50","author":"M Narazaki","year":"2011","unstructured":"Narazaki M, Hagihara K, Shima Y, Ogata A, Kishimoto T, Tanaka T. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford). 2011;50:1344\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"48_CR77","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/rheumatology\/ker088","volume":"50","author":"EA Mahler","year":"2011","unstructured":"Mahler EA, Blom M, Voermans NC, van Engelen BG, van Riel PL, Vonk MC, et al. Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology (Oxford). 2011;50:2206\u201313.","journal-title":"Rheumatology (Oxford)"},{"key":"48_CR78","first-page":"1864","volume":"34","author":"CC Mok","year":"2007","unstructured":"Mok CC, Ho LY, To CH. Rituximab for refractory polymyositis: an open-label prospective study. J Rheumatol. 2007;34:1864\u20138.","journal-title":"J Rheumatol"},{"key":"48_CR79","first-page":"1021","volume":"33","author":"EH Noss","year":"2006","unstructured":"Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol. 2006;33:1021\u20136.","journal-title":"J Rheumatol"},{"key":"48_CR80","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.reuma.2012.02.007","volume":"9","author":"S\u00c1 S\u00e1nchez-Fern\u00e1ndez","year":"2013","unstructured":"S\u00e1nchez-Fern\u00e1ndez S\u00c1, Carrasco Fern\u00e1ndez JA, Rojas Vargas LM. Efficacy of rituximab in dermatomyositis and polymyositis refractory to conventional therapy. Reumatol Clin. 2013;9:117\u20139.","journal-title":"Reumatol Clin"},{"key":"48_CR81","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1093\/rheumatology\/kep147","volume":"48","author":"F Frikha","year":"2009","unstructured":"Frikha F, Rigolet A, Behin A, Fautrel B, Herson S, Benveniste O. Efficacy of rituximab in refractory and relapsing myositis with anti-Jo-1 antibodies: a report of two cases. Rheumatology (Oxford). 2009;48:1166\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"48_CR82","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1093\/rheumatology\/keu024","volume":"53","author":"L Unger","year":"2014","unstructured":"Unger L, Kampf S, L\u00fcthke K, Aringer M. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population. Rheumatology (Oxford). 2014;53:1630\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"48_CR83","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/art.20849","volume":"52","author":"TD Levine","year":"2005","unstructured":"Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005;52:601\u20137.","journal-title":"Arthritis Rheum"},{"key":"48_CR84","first-page":"1369","volume":"32","author":"O Lambotte","year":"2005","unstructured":"Lambotte O, Kotb R, Maigne G, Blanc FX, Goujard C, Delfraissy JF. Efficacy of rituximab in refractory polymyositis. J Rheumatol. 2005;32:1369\u201370.","journal-title":"J Rheumatol"},{"key":"48_CR85","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"CV Oddis","year":"2013","unstructured":"Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, RIM Study Group, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65:314\u201324.","journal-title":"Arthritis Rheum"},{"key":"48_CR86","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12891-015-0710-3","volume":"16","author":"AM Reed","year":"2015","unstructured":"Reed AM, Crowson CS, Hein M, de Padilla CL, Olazagasti JM, Aggarwal R, RIM Study Group, et al. Biologic predictors of clinical improvement in rituximab-treated refractory myositis. BMC Musculoskelet Disord. 2015;16:257.","journal-title":"BMC Musculoskelet Disord"},{"key":"48_CR87","doi-asserted-by":"publisher","first-page":"e0133702","DOI":"10.1371\/journal.pone.0133702","volume":"10","author":"Y Allenbach","year":"2015","unstructured":"Allenbach Y, Guiguet M, Rigolet A, Marie I, Hachulla E, Drouot L, et al. Efficacy of rituximab in refractory inflammatory myopathies associated with anti-synthetase auto-antibodies: an open-label, phase II trial. PLoS One. 2015;10:e0133702.","journal-title":"PLoS One"},{"key":"48_CR88","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/B978-0-7020-4086-3.00032-1","volume":"119","author":"AJ Kooi van der","year":"2014","unstructured":"van der Kooi AJ, de Visser M. Idiopathic inflammatory myopathies. Handb Clin Neurol. 2014;119:495\u2013512.","journal-title":"Handb Clin Neurol"},{"key":"48_CR89","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1056\/NEJMra1402225","volume":"372","author":"MC Dalakas","year":"2015","unstructured":"Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;372:1734\u201347.","journal-title":"N Engl J Med"},{"key":"48_CR90","first-page":"441","volume":"17","author":"A Nzeusseu","year":"1999","unstructured":"Nzeusseu A, Brion F, Lef\u00e8bvre C, Knoops P, Devogelaer JP, et al. Functional outcome of myositis patients: can a low-dose glucocorticoid regimen achieve good functional results? Clin Exp Rheumatol. 1999;17:441\u20136.","journal-title":"Clin Exp Rheumatol"},{"key":"48_CR91","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.nmd.2010.03.011","volume":"20","author":"J Vlekkert van de","year":"2010","unstructured":"van de Vlekkert J, Hoogendijk JE, de Haan RJ, Algra A, van der Tweel I, van der Pol WL, et al. Dexa myositis trial. Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomized clinical trial. Neuromuscul Disord. 2010;20:382\u20139.","journal-title":"Neuromuscul Disord"},{"key":"48_CR92","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000338474","volume":"68","author":"M Uchino","year":"2012","unstructured":"Uchino M, Yamashita S, Uchino K, Hara A, Koide T, Suga T, et al. Long-term outcome of polymyositis treated with high single-dose alternate-day prednisolone therapy. Eur Neurol. 2012;68:117\u201321.","journal-title":"Eur Neurol"},{"key":"48_CR93","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/art.23829","volume":"59","author":"R Seshadri","year":"2008","unstructured":"Seshadri R, Feldman BM, Ilowite N, Cawkwell G, Pachman LM. The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. Arthritis Rheum. 2008;59:989\u201395.","journal-title":"Arthritis Rheum"},{"key":"48_CR94","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/MJT.0000000000000175","volume":"22","author":"P Raghu","year":"2015","unstructured":"Raghu P, Manadan AM, Schmukler J, Mathur T, Block JA. Pulse dose methylprednisolone therapy for adult idiopathic inflammatory myopathy. Am J Ther. 2015;22:244\u20137.","journal-title":"Am J Ther"},{"key":"48_CR95","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/MJT.0b013e3182987983","volume":"22","author":"T Mathur","year":"2015","unstructured":"Mathur T, Manadan AM, Thiagarajan S, Hota B, Block JA. Corticosteroid monotherapy is usually insufficient treatment for idiopathic inflammatory myopathy. Am J Ther. 2015;22:350\u20134.","journal-title":"Am J Ther"},{"key":"48_CR96","first-page":"451","volume":"18","author":"M Mosca","year":"2000","unstructured":"Mosca M, Neri R, Pasero G, Bombardieri S. Treatment of the idiopathic inflammatory myopathies: a retrospective analysis of 63 Caucasian patients longitudinally followed at a single center. Clin Exp Rheumatol. 2000;18:451\u20136.","journal-title":"Clin Exp Rheumatol"},{"key":"48_CR97","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1136\/ard.2005.045690","volume":"65","author":"IM Bronner","year":"2006","unstructured":"Bronner IM, van der Meulen MF, de Visser M, Kalmijn S, van Venrooij WJ, Voskuyl AE, et al. Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis. 2006;65:1456\u201361.","journal-title":"Ann Rheum Dis"},{"key":"48_CR98","first-page":"2230","volume":"28","author":"I Marie","year":"2001","unstructured":"Marie I, Hachulla E, Hatron PY, Hellot MF, Levesque H, Devulder B, et al. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol. 2001;28:2230\u20137.","journal-title":"J Rheumatol"},{"key":"48_CR99","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/030097400750001897","volume":"29","author":"J Vencovsk","year":"2000","unstructured":"Vencovsk J, Jarosov K, Machcek S, Studnkov J, Kafkov J, Bartunkov\u00e1 J, et al. Cyclosporine a versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol. 2000;29:95\u2013102.","journal-title":"Scand J Rheumatol"},{"key":"48_CR100","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/rheumatology\/keu442","volume":"54","author":"F Ibrahim","year":"2015","unstructured":"Ibrahim F, Choy E, Gordon P, Dor CJ, Hakim A, Kitas G, et al. Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids. Rheumatology (Oxford). 2015;54:1050\u20135.","journal-title":"Rheumatology (Oxford)"},{"key":"48_CR101","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/rheumatology\/kel336","volume":"46","author":"CN Pisoni","year":"2007","unstructured":"Pisoni CN, Cuadrado MJ, Khamashta MA, Hughes GR, D'Cruz DP. Mycophenolate mofetil treatment in resistant myositis. Rheumatology (Oxford). 2007;46:516\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"48_CR102","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/rheumatology\/keh499","volume":"44","author":"V Majithia","year":"2005","unstructured":"Majithia V, Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford). 2005;44:386\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"48_CR103","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00296-010-1653-5","volume":"32","author":"R Dagher","year":"2012","unstructured":"Dagher R, Desjonqures M, Duquesne A, Quartier P, Bader-Meunier B, Fischbach M, et al. Mycophenolate mofetil in juvenile dermatomyositis: a case series. Rheumatol Int. 2012;32:711\u20136.","journal-title":"Rheumatol Int"},{"key":"48_CR104","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.rmed.2013.02.015","volume":"107","author":"IC Mira-Avendano","year":"2013","unstructured":"Mira-Avendano IC, Parambil JG, Yadav R, Arrossi V, Xu M, Chapman JT, et al. A retrospective review of clinical features and treatment outcomes in steroid resistant interstitial lung disease from polymyositis \/ dermatomyositis. Respir Med. 2013;107:890\u20136.","journal-title":"Respir Med"},{"key":"48_CR105","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/acr.20212","volume":"62","author":"PA Morganroth","year":"2010","unstructured":"Morganroth PA, Kreider ME, Werth VP. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res (Hoboken). 2010;62:1496\u2013501.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"48_CR106","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1093\/brain\/awf163","volume":"125","author":"G Cea","year":"2002","unstructured":"Cea G, Bendahan D, Manners D, Hilton-Jones D, Lodi R, Styles P, et al. Reduced oxidative phosphorylation and proton efflux suggest reduced capillary blood supply in skeletal muscle of patients with dermatomyositis and polymyositis: a quantitative 31P - magnetic resonance spectroscopy and MRI study. Brain. 2002;125:1635\u201345.","journal-title":"Brain"},{"key":"48_CR107","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1002\/art.10140","volume":"46","author":"P Englund","year":"2002","unstructured":"Englund P, Nennesmo I, Klareskog L, Lundberg IE. Interleukin-1 alpha expression in capillaries and major histocompatibility complex class I expression in type II muscle fibers from polymyositis and dermatomyositis patients: important pathogenic features independent of inflammatory cell clusters in muscle tissue. Arthritis Rheum. 2002;46:1044\u201355.","journal-title":"Arthritis Rheum"},{"key":"48_CR108","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.1365-2796.2010.02334.x","volume":"269","author":"I Loell","year":"2011","unstructured":"Loell I, Lundberg IE. Can muscle regeneration fail in chronic inflammation: a weakness in inflammatory myopathies? J Intern Med. 2011;269:243\u201357.","journal-title":"J Intern Med"},{"key":"48_CR109","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1191\/0269215503cr572oa","volume":"17","author":"C Varj\u00fa","year":"2003","unstructured":"Varj\u00fa C, Peth\u00f6 E, Kutas R, Czirj\u00e1k L. The effect of physical exercise following acute disease exacerbation in patients with dermato\/polymyositis. Clin Rehabil. 2003;17:83\u20137.","journal-title":"Clin Rehabil"},{"key":"48_CR110","first-page":"161","volume":"50","author":"F Bertolucci","year":"2014","unstructured":"Bertolucci F, Neri R, Dalise S, Venturi M, Rossi B, Crisari C. Abnormal lactate levels in patients with polymyositis and dermatomyositis: the benefits of a specific rehabilitative program. Eur J Phys Rehabil Med. 2014;50:161\u20139.","journal-title":"Eur J Phys Rehabil Med"},{"key":"48_CR111","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/rheumatology\/37.2.196","volume":"37","author":"GF Wiesinger","year":"1998","unstructured":"Wiesinger GF, Quittan M, Aringer M, Seeber A, Volc-Platzer B, Smolen J, et al. Improvement of physical fitness and muscle strength in polymyositis\/dermatomyositis patients by a training programme. Br J Rheumatol. 1998;37:196\u2013200.","journal-title":"Br J Rheumatol"},{"key":"48_CR112","first-page":"1399","volume":"20","author":"JE Hicks","year":"1993","unstructured":"Hicks JE, Miller F, Plotz P, Chen TH, Gerber L. Isometric exercise increases strength and does not produce sustained creatinine phosphokinase increases in a patient with polymyositis. J Rheumatol. 1993;20:1399\u2013401.","journal-title":"J Rheumatol"},{"key":"48_CR113","first-page":"1340","volume":"20","author":"A Escalante","year":"1993","unstructured":"Escalante A, Miller L, Beardmore TD. Resistive exercise in the rehabilitation of polymyositis\/dermatomyositis. J Rheumatol. 1993;20:1340\u20134.","journal-title":"J Rheumatol"},{"key":"48_CR114","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/BOR.0b013e3283319d53","volume":"21","author":"GA Nader","year":"2009","unstructured":"Nader GA, Lundberg IE. Exercise as an anti-inflammatory intervention to combat inflammatory diseases of muscle. Curr Opin Rheumatol. 2009;21:599\u2013603.","journal-title":"Curr Opin Rheumatol"},{"key":"48_CR115","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2119\/molmed.2010.00016","volume":"16","author":"GA Nader","year":"2010","unstructured":"Nader GA, Dastmalchi M, Alexanderson H, Grundtman C, Gernapudi R, Esbj\u00f6rnsson M, et al. A longitudinal, integrated, clinical, histological and mRNA profiling study of resistance exercise in myositis. Mol Med. 2010;16:455\u201364.","journal-title":"Mol Med"},{"key":"48_CR116","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1002\/art.39624","volume":"68","author":"LA Munters","year":"2016","unstructured":"Munters LA, Loell I, Ossipova E, Raouf J, Dastmalchi M, Lindroos E, et al. Endurance exercise improves molecular pathways of aerobic metabolism in patients with myositis. Arthritis Rheumatol. 2016;68:1738\u201350.","journal-title":"Arthritis Rheumatol"},{"key":"48_CR117","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183292","volume":"12","author":"JF Boehler","year":"2017","unstructured":"Boehler JF, Hogarth MW, Barberio MD, Novak JS, Ghimbovschi S, Brown KJ, et al. Effect of endurance exercise on microRNAs in myositis skeletal muscle - a randomized controlled study. PLoS One. 2017;12:e0183292.","journal-title":"PLoS One"},{"key":"48_CR118","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3899\/jrheum.131145","volume":"41","author":"H Alexanderson","year":"2014","unstructured":"Alexanderson H, Munters LA, Dastmalchi M, Loell I, Heimb\u00fcrger M, Opava CH, et al. Resistive home exercise in patients with recent-onset polymyositis and dermatomyositis - a randomized controlled single-blinded study with a 2-year followup. J Rheumatol. 2014;41:1124\u201332.","journal-title":"J Rheumatol"},{"key":"48_CR119","doi-asserted-by":"publisher","first-page":"R83","DOI":"10.1186\/ar4263","volume":"15","author":"L Alemo Munters","year":"2013","unstructured":"Alemo Munters L, Dastmalchi M, Katz A, Esbj\u00f6rnsson M, Loell I, Hanna B, et al. Improved exercise performance and increased aerobic capacity after endurance training of patients with stable polymyositis and dermatomyositis. Arthritis Res Ther. 2013;15:R83.","journal-title":"Arthritis Res Ther."},{"key":"48_CR120","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1002\/acr.22068","volume":"65","author":"L Alemo Munters","year":"2013","unstructured":"Alemo Munters L, Dastmalchi M, Andgren V, Emilson C, Bergeg\u00e5rd J, Regardt M, et al. Improvement in health and possible reduction in disease activity using endurance exercise in patients with established polymyositis and dermatomyositis: a multicenter randomized controlled trial with a 1-year open extension follow-up. Arthritis Care Res (Hoboken). 2013;65:1959\u201368.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"48_CR121","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.apmr.2016.09.125","volume":"98","author":"V Tiffreau","year":"2017","unstructured":"Tiffreau V, Rannou F, Kopciuch F, Hachulla E, Mouthon L, Thoumie P, et al. Post rehabilitation functional improvements in patients with inflammatory myopathies: the results of a randomized controlle trial. Arch Phys Med Rehabil. 2017;98:227\u201334.","journal-title":"Arch Phys Med Rehabil"},{"key":"48_CR122","first-page":"655","volume":"33","author":"CM L\u00f3pez De Padilla","year":"2015","unstructured":"L\u00f3pez De Padilla CM, Crowson CS, Hein MS, Strausbauch MA, Aggarwal R, Levesque MC, et al. Interferon-regulated chemokine score associated with improvement in disease activity in refractory myositis patients treated with rituximab. Clin Exp Rheumatol. 2015;33:655\u201363.","journal-title":"Clin Exp Rheumatol"},{"key":"48_CR123","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1093\/rheumatology\/keu258","volume":"53","author":"T Gono","year":"2014","unstructured":"Gono T, Kaneko H, Kawaguchi Y, Hanaoka M, Kataoka S, Kuwana M, et al. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology (Oxford). 2014;53:2196\u2013203.","journal-title":"Rheumatology (Oxford)"},{"key":"48_CR124","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11926-015-0543-y","volume":"17","author":"JM Olazagasti","year":"2015","unstructured":"Olazagasti JM, Niewold TB, Reed AM. Immunological biomarkers in dermatomyositis. Curr Rheumatol Rep. 2015;17:68.","journal-title":"Curr Rheumatol Rep"},{"key":"48_CR125","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3233\/JND-170234","volume":"4","author":"UA Badrising","year":"2017","unstructured":"Badrising UA, Tsonaka R, Hiller M, Niks EH, Evangelista T, Lochm\u00fcller H, et al. Cytokine profiling of serum allows monitoring of disease progression in inclusion body myositis. J Neuromuscul Dis. 2017;4:327\u201335.","journal-title":"J Neuromuscul Dis"},{"key":"48_CR126","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1136\/ard.2008.091405","volume":"68","author":"O Krystufkov\u00e1","year":"2009","unstructured":"Krystufkov\u00e1 O, Vallerskog T, Helmers SB, Mann H, Putov\u00e1 I, Bel\u00e1cek J, et al. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann Rheum Dis. 2009;68:836\u201343.","journal-title":"Ann Rheum Dis"},{"key":"48_CR127","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1002\/art.34659","volume":"64","author":"AM Reed","year":"2012","unstructured":"Reed AM, Peterson E, Bilgic H, Ytterberg SR, Amin S, Hein MS, et al. Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course. Arthritis Rheum. 2012;64:4078\u201386.","journal-title":"Arthritis Rheum"},{"key":"48_CR128","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.3899\/jrheum.140977","volume":"42","author":"N Kobayashi","year":"2015","unstructured":"Kobayashi N, Kobayashi I, Mori M, Sato S, Iwata N, Shiguemura T, et al. Increased serum B cell activating factor and a proliferation-inducing ligand are associated with interstitial lung disease in patients with juvenile dermatomyositis. J Rheumatol. 2015;42:2412\u20138.","journal-title":"J Rheumatol"},{"key":"48_CR129","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1093\/rheumatology\/39.6.632","volume":"39","author":"M Kubo","year":"2000","unstructured":"Kubo M, Ihn H, Yamane K, Kikuchi K, Yazawa N, Soma Y, et al. Serum KL-6 in adult patients with polymyositis and dermatomyositis. Rheumatology (Oxford). 2000;39:632\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"48_CR130","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/j.1365-2796.2011.02459.x","volume":"271","author":"M Fathi","year":"2012","unstructured":"Fathi M, Barbasso Helmers S, Lundberg IE. KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis. J Intern Med. 2012;271:589\u201397.","journal-title":"J Intern Med"},{"key":"48_CR131","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/imj.12754","volume":"45","author":"F Chen","year":"2015","unstructured":"Chen F, Lu X, Shu X, Peng Q, Tian X, Wang G. Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study. Intern Med J. 2015;45:641\u20137.","journal-title":"Intern Med J"},{"key":"48_CR132","doi-asserted-by":"publisher","first-page":"R131","DOI":"10.1186\/ar4311","volume":"15","author":"K Nistala","year":"2013","unstructured":"Nistala K, Varsani H, Wittkowski H, Vogl T, Krol P, Shah V, et al. Myeloid related protein induces muscle derived inflammatory mediators in juvenile dermatomyositis. Arthritis Res Ther. 2013;15:R131.","journal-title":"Arthritis Res Ther."},{"key":"48_CR133","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12950-015-0075-2","volume":"12","author":"JM Olazagasti","year":"2015","unstructured":"Olazagasti JM, Hein M, Crowson CS, de Padilla CL, Peterson E, Baechler EC, et al. Adipokine gene expression in peripheral blood of adult and juvenile dermatomyositis patients and their relation to clinical parameters and disease activity measures. J Inflamm (Lond). 2015;12:29.","journal-title":"J Inflamm (Lond)"},{"key":"48_CR134","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1002\/art.38676","volume":"66","author":"F Bellutti Enders","year":"2014","unstructured":"Bellutti Enders F, van Wijk F, Scholman R, Hofer M, Prakken BJ, van Royen-Kerkhof A, de Jager W. Correlation of CXCL10, tumor necrosis factor receptor type II, and galectin 9 with disease activity in juvenile dermatomyositis. Arthritis Rheumatol. 2014;66:2281\u20139.","journal-title":"Arthritis Rheumatol."},{"key":"48_CR135","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","volume":"14","author":"NJ McHugh","year":"2018","unstructured":"McHugh NJ, Tansley SL. Autoantibodies in myositis. Nat Rev Rheumatol. 2018;14:290\u2013302.","journal-title":"Nat Rev Rheumatol"},{"key":"48_CR136","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/rheumatology\/kev444","volume":"55","author":"R Aggarwal","year":"2016","unstructured":"Aggarwal R, Oddis CV, Goudeau D, Koontz D, Qi Z, Reed AM, et al. Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab. Rheumatology (Oxford). 2016;55:991\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"48_CR137","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3109\/14397595.2015.1054081","volume":"26","author":"M Ishizuka","year":"2016","unstructured":"Ishizuka M, Watanabe R, Ishii T, Machiyama T, Akita K, Fujita Y, et al. Long-term follow-up of 124 patients with polymyositis and dermatomyositis: statistical analysis of prognostic factors. Mod Rheumatol. 2016;26:115\u201320.","journal-title":"Mod Rheumatol"},{"key":"48_CR138","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","volume":"362","author":"MC Dalakas","year":"2003","unstructured":"Dalakas MC. Polymyositis and dermatomyositis. Lancet. 2003;362:971\u201382.","journal-title":"Lancet"},{"key":"48_CR139","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1136\/jnnp.2008.161448","volume":"80","author":"K Nozaki","year":"2009","unstructured":"Nozaki K, Pestronk A. High aldolase with normal creatine kinase in serum predicts a myopathy with perimysial pathology. J Neurol Neurosurg Psychiatry. 2009;80:904\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"48_CR140","first-page":"603","volume":"30","author":"LG Rider","year":"2003","unstructured":"Rider LG, Giannini EH, Harris-Love M, Joe G, Isenberg D, Pilkington C, International Myositis Assessment and Clinical Studies Group, et al. Defining clinical improvement in adult and juvenile myositis. J Rheumatol. 2003;30:603\u201317.","journal-title":"J Rheumatol"},{"key":"48_CR141","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1002\/art.21291","volume":"52","author":"CV Oddis","year":"2005","unstructured":"Oddis CV, Rider LG, Reed AM, Ruperto N, Brunner HI, Koneru B, International Myositis Assessment and Clinical Studies Group, et al. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum. 2005;52:2607\u201315.","journal-title":"Arthritis Rheum"},{"key":"48_CR142","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","volume":"76","author":"R Aggarwal","year":"2017","unstructured":"Aggarwal R, Rider L, Ruperto N, Bayat N, Erman B, Feldman BM, et al. 2016 American College of Rheumatology (ACR)- European league against rheumatism (EULAR) criteria for minimal, moderate and major clinical response for adult dermatomyositis and polymyositis: an international myositis assessment and clinical studies group\/ pediatric rheumatology international trials organization collaborative initiative. Ann Rheum Dis. 2017;76:792\u2013801.","journal-title":"Ann Rheum Dis"},{"key":"48_CR143","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12969-017-0154-4","volume":"15","author":"R Abdul-Aziz","year":"2017","unstructured":"Abdul-Aziz R, Yu CY, Adler B, Bout-Tabaku S, Lintner KE, Moore-Clingenpeel M, et al. Muscle MRI at the time of questionable disease flares in juvenile dermatomyositis (JDM). Pediatr Rheumatol Online J. 2017;15:25.","journal-title":"Pediatr Rheumatol Online J"},{"key":"48_CR144","first-page":"441","volume":"55","author":"L Yao","year":"2016","unstructured":"Yao L, Yip AL, Shrader JA, Mesdaghinia S, Volochayev R, Jansen AV, et al. Magnetic resonance measurement of muscle T2, fat-corrected T2 and fat fraction in the assessment of idiopathic inflammatory myopathies. Rheumatology (Oxford). 2016;55:441\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"48_CR145","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.semarthrit.2016.11.001","volume":"46","author":"J Day","year":"2017","unstructured":"Day J, Patel S, Limaye V. The role of magnetic resonance imaging techniques in evaluation and management of the idiopathic inflammatory myopathies. Semin Arthritis Rheum. 2017;46:642\u20139.","journal-title":"Semin Arthritis Rheum"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-019-0048-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s42358-019-0048-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-019-0048-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T01:06:32Z","timestamp":1579655192000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-019-0048-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,22]]},"references-count":145,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["48"],"URL":"https:\/\/doi.org\/10.1186\/s42358-019-0048-x","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,22]]},"assertion":[{"value":"4 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"6"}}